NASDAQ:SUPN Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis $32.85 -0.12 (-0.36%) Closing price 04:00 PM EasternExtended Trading$32.87 +0.02 (+0.06%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Supernus Pharmaceuticals Stock (NASDAQ:SUPN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SUPN alerts:Sign Up Key Stats Today's Range$32.51▼$33.4150-Day Range$31.16▼$33.9652-Week Range$27.05▼$40.28Volume540,341 shsAverage Volume698,889 shsMarket Capitalization$1.84 billionP/E Ratio29.59Dividend YieldN/APrice Target$36.00Consensus RatingHold Company Overview Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. Read More Supernus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreSUPN MarketRank™: Supernus Pharmaceuticals scored higher than 35% of companies evaluated by MarketBeat, and ranked 722nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSupernus Pharmaceuticals has received no research coverage in the past 90 days.Read more about Supernus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-39.50% Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to decrease by -39.50% in the coming year, from $2.38 to $1.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is 29.59, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is 29.59, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.90.Price to Book Value per Share RatioSupernus Pharmaceuticals has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Supernus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.25% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently increased by 21.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-2.35 Percentage of Shares Shorted9.25% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently increased by 21.59%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.60 News SentimentSupernus Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Supernus Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest2 people have searched for SUPN on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.80% of the stock of Supernus Pharmaceuticals is held by insiders.Read more about Supernus Pharmaceuticals' insider trading history. Receive SUPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SUPN Stock News HeadlinesSupernus Pharmaceuticals Inc (SUPN) Announces Upcoming Q2 2025 Financial Results Release | SUPN ...July 22 at 5:25 PM | gurufocus.comSupernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025July 22 at 4:30 PM | globenewswire.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 24 at 2:00 AM | Brownstone Research (Ad)Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered to Hold at Wall Street ZenJuly 22 at 2:56 AM | americanbankingnews.comWhy Supernus Pharmaceuticals (SUPN) Shares Are Falling TodayJuly 18, 2025 | msn.comSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJuly 14, 2025 | businesswire.com2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with CautionJuly 10, 2025 | finance.yahoo.comBranded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)July 9, 2025 | msn.comSee More Headlines SUPN Stock Analysis - Frequently Asked Questions How have SUPN shares performed this year? Supernus Pharmaceuticals' stock was trading at $36.16 at the beginning of 2025. Since then, SUPN stock has decreased by 9.2% and is now trading at $32.85. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its quarterly earnings results on Monday, November, 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. The firm's quarterly revenue was up 14.2% compared to the same quarter last year. Read the conference call transcript. Who are Supernus Pharmaceuticals' major shareholders? Top institutional investors of Supernus Pharmaceuticals include Wedge Capital Management L L P NC (0.13%), Campbell Newman Asset Management Inc. (0.08%), State of Alaska Department of Revenue (0.06%) and QRG Capital Management Inc. (0.03%). Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Georges Gemayel, Padmanabh P Bhatt, Frank Mottola and Jonathan Rubin. View institutional ownership trends. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY). Company Calendar Last Earnings11/04/2024Today7/24/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SUPN CIK1356576 Webwww.supernus.com Phone(301) 838-2500Fax301-838-2501Employees580Year FoundedN/APrice Target and Rating Average Price Target for Supernus Pharmaceuticals$36.00 High Price Target$36.00 Low Price Target$36.00 Potential Upside/Downside+9.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$1.11 Trailing P/E Ratio29.59 Forward P/E Ratio13.80 P/E GrowthN/ANet Income$73.86 million Net Margins9.27% Pretax Margin13.74% Return on Equity12.23% Return on Assets9.17% Debt Debt-to-Equity RatioN/A Current Ratio2.44 Quick Ratio2.26 Sales & Book Value Annual Sales$668.00 million Price / Sales2.75 Cash Flow$4.15 per share Price / Cash Flow7.91 Book Value$18.76 per share Price / Book1.75Miscellaneous Outstanding Shares55,990,000Free Float51,063,000Market Cap$1.84 billion OptionableOptionable Beta0.70 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:SUPN) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.